When was Immutrix Therapeutics founded?

Immutrix Therapeutics was founded in 2009 and raised its 1st funding round 6 years after it was founded.

Where is Immutrix Therapeutics located?

Immutrix Therapeutics is headquartered in Rapid City, United States.

Who is the current CEO of Immutrix Therapeutics?

Carol Rae of Immutrix Therapeutics. They have also founded 1 company.

How many employees does Immutrix Therapeutics have?

As of Sep 30, 2026, the latest employee count at Immutrix Therapeutics is 17.

Is Immutrix Therapeutics a funded company?

Immutrix Therapeutics is a funded company, having raised a total of $14M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 20, 2015.

When was the latest funding round of Immutrix Therapeutics?

Immutrix Therapeutics' latest funding was a $***** Conventional Debt round on Sep 18, 2025, with participation from 0 investor.

Where does Immutrix Therapeutics rank among its competitors?

Immutrix Therapeutics ranks 4th amongst 10 active competitors, of which 4 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Immutrix Therapeutics, which secured $480K in Sep, 2025.

Who are the top competitors of Immutrix Therapeutics?

Immutrix Therapeutics' top competitors include Haemonetics, Vetex Medical and MediSieve. Among them, Immutrix Therapeutics secured the most recent funding round in September, 2025.

Immutrix Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Immutrix Therapeutics is a series A company based in Rapid City (United States), founded in 2009 by Carol Rae. It operates as an Innovating blood filtration technologies for critical care and unmet medical needs. Immutrix Therapeutics has raised $14M in funding. The company has 10 active competitors, including 4 funded and 3 that have exited. Its top competitors include companies like Haemonetics, Vetex Medical and MediSieve.

Company Details

Innovating blood filtration technologies for critical care and unmet medical needs. The company develops cutting-edge extracorporeal blood-filtration technologies, addressing urgent, unmet medical needs. Their lead innovation is a proprietary hemoperfusion device, a dialysis-like procedure that removes harmful molecules from circulating blood while preserving essential components. This technology targets toxins, poisons, and immune mediators, interrupting pathological cascades that lead to complications. The company's engineered carbon materials rapidly reduce harmful substances from blood, preserving platelets, albumin, and electrolytes. This positions them as a leader in next-generation, rapid-response therapies for acute, acute-on-chronic, and chronic medical conditions. They operate at the intersection of immunology, toxicology, and critical care medicine, focusing on emergency and intensive care. Their research and development efforts are geared towards commercializing proprietary therapeutic treatments using advanced adsorbent technologies, specifically for the removal of drugs and poisons.

Website: immutrix.com/cgi-sys/suspendedpage.cgi
Phone Number: +1 **********

Key Metrics

Founded Year

2009

Location

Rapid City, United States

Stage

Series A

Total Funding

$14M in 6 rounds

Latest Funding Round

Conventional Debt, Sep 18, 2025, $*****

Ranked

4^th among 10 active competitors

Employee Count

17 as on Sep 30, 2026

Similar Companies

Haemonetics & 10 more

View Immutrix Therapeutics' full profile

Immutrix Therapeutics has raised a total funding of $14M over 6 rounds. Its first funding round was on Oct 20, 2015.

Here is the list of recent funding rounds of Immutrix Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 18, 2025	8031347	Conventional Debt	9051441	9945786	7209307	7188909
Jul 01, 2020	3067187	Series A	8789234	1238306	4412074	6497802
Sep 05, 2019	4074094	Series A	6535315	1754821	2204338	3720727

Access funding benchmarks and valuations. Sign up today!

View details of Immutrix Therapeutics's funding rounds and investors

The founders of Immutrix Therapeutics is Carol Rae. Carol Rae is the CEO of Immutrix Therapeutics.

Here are the details of Immutrix Therapeutics' key team members:

Carol Rae: Founder & CEO of Immutrix Therapeutics.
Contact Info: 1 email address and 1 phone number

View details of Immutrix Therapeutics's Founder profiles and Board Members

Immutrix Therapeutics' employee count trend

Immutrix Therapeutics has 17 employees as of Sep 26. Here is Immutrix Therapeutics's employee count trend over the years:

Employee count trend for Immutrix Therapeutics

Uncover Immutrix Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Immutrix Therapeutics include Haemonetics, Vetex Medical and MediSieve. Here is the list of Top 10 competitors of Immutrix Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Haemonetics 1971, Braintree (United States), Public	Provider of hematology products and solutions for the medical industry	-	Blum Capital, Partners For Growth & 1 others	62/100
2nd	Vetex Medical 2016, Galway (Ireland), Acquired	Developer of catheter for clot management in veins	-	EIC Fund, European Innovation Council & 1 others	41/100
3rd	MediSieve 2014, London (United Kingdom), Series A	Developer of magnetic therapy to treat blood borne diseases	$4.18M	24 Haymarket, EIC Fund & 23 others	40/100
4th	Immutrix Therapeutics 2009, Rapid City (United States), Series A	Innovating blood filtration technologies for critical care and unmet medical needs	$14M	-	35/100
5th	Plasmology4 2010, Scottsdale (United States), Seed	Cold plasma treatment	$6.39M	-	35/100
6th	Straub Medical 1997, Vilters Wangs (Switzerland), Acquired	Developer of a device for treating blood vessel diseases	-	-	32/100
7th	Redfield Corporation 1987, Rochelle Park (United States), Funding Raised	Infrared coagulation solutions for hemorrhoid treatment, anal dysplasia, and more	-	United States Department of Agriculture	23/100
8th	Excorp Medical 1995, Minneapolis (United States), Unfunded	Developer of a bioartificial liver system to support acute liver failure	-	-	22/100
9th	Exvivodynamics 2013, New York City (United States), Funding Raised	Medical device to filter blood for transfusion	-	Design Technologies	22/100
10th	Five Liters 2022, Dallas (United States), Seed	Developer of medical device for non-invasive neuromodulation of hemorrhaging	$500K	Pathwaytocures	17/100